Drug firm AstraZeneca Pharma India Friday said it has entered into a distribution agreement with Abbott Healthcare for distribution of diabetes medicine Dapagliflozin in India. Under the agreement, Abbott will promote and distribute Dapagliflozin under t https://health.economictimes.indiatimes.com/news/pharma/astrazeneca-pharma-inks-distribution-pact-with-abbott-for-diabetes-drug/66982577

Real world data from a large Nordic study shows that use of liraglutide, a drug for type 2 diabetes, is associated with a lower risk of myocardial infarction, stroke or cardiovascular death. The study, led by researchers from Karolinska Institutet in Swe https://www.news-medical.net/news/20181206/Liraglutide-drug-associated-with-lower-risk-of-cardiovascular-events.aspx

For Medtronic, diabetes management is a big business, and the firm is seeking a differentiated set of solutions to help patients (and customers) manage their blood sugar through effective food and nutrition information. https://seekingalpha.com/article/4226503-medtronic-acquire-nutrino-health-nutrition-data-tech

Nemaura Medical Inc., a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today reported that it has successfully completed the c https://globenewswire.com/news-release/2018/12/04/1661588/0/en/Nemaura-Successfully-Completes-Clinical-Studies-for-SugarBEAT-FDA-De-Novo-510-k-Submission.html

POPS! Diabetes Care is announcing the U.S. Food and Drug Administration (FDA) clearance of their POPS!® one Blood Glucose Monitoring System. The system is designed to enable people with diabetes to successfully control their condition without their condi https://www.businesswire.com/news/home/20181204005824/en/POPS%21-Diabetes-Care-Announces-FDA-Clearance-POPS%21®

Lexicon Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) plans to review Lexicon collaborator Sanofi’s New Drug Application (NDA) for sotagliflozin, an i https://globenewswire.com/news-release/2018/11/29/1659016/0/en/FDA-Advisory-Committee-to-Review-Investigational-Sotagliflozin-as-Potential-Treatment-for-Type-1-Diabetes.html

Medtronic announced plans to absorb Nutrino Health, a nutrition-focused data analytics company, and further integrate its work with its diabetes group. Financial terms were not disclosed. The medtech giant previously worked with Nutrino in a multiyear pa https://www.fiercebiotech.com/medtech/medtronic-to-acquire-nutrition-ai-firm-nutrino-for-its-digital-diabetes-projects

The American Diabetes Association estimates that over 30 million Americans are affected by diabetes and is the seventh leading cause of death in the United States. In the African American population, studies show that we are disproportionately affected b https://www.theskanner.com/news/usa/27773-eli-lilly-announces-lilly-diabetes-solutions-center-to-assist-people-with-insulin-affordability

Diabeloop announced this month it has received the CE marking for its “artificial pancreas system,” dubbed the DBLG1,™ for adults with type 1 diabetes. Receiving a CE mark is an important step towards the commercial release of the product in Europe, whic https://dlife.com/diabeloop-gets-regulatory-approval-for-artificial-pancreas-system-in-europe/

This study aimed to compare the cardiometabolic effects of dapagliflozin and vildagliptin in type 2 diabetes patients with coronary artery disease. Researchers conducted a randomized, double-blind, single-center study in which 43 patients with type 2 dia https://www.healio.com/cardiology/diabetes/news/online/%7B22c6a305-8e42-4fc9-9187-a9c2d132362f%7D/dapagliflozin-confers-more-favorable-cardiometabolic-outcomes-vs-vildagliptin